Insmed registers Phase 3 trial of inhaled TPIP for progressive pulmonary fibrosis
New PALM-PPF study will test once-daily TPIP against placebo in adults with progressive pulmonary fibrosis, targeting 800 participants.
This week's registry update covers a newly listed Phase 3 trial from Insmed.
- Insmed has registered a Phase 3 trial, "PALM-PPF" (NCT07805785), testing Treprostinil Palmitil Inhalation Powder (TPIP) against placebo in adults with progressive pulmonary fibrosis. The study is not yet recruiting, with an estimated start date of December 2026 and estimated primary completion of August 2030.1 The trial plans to enroll 800 participants, using a randomized, quadruple-masked design1, with the primary outcome being change from baseline in absolute Forced Vital Capacity (FVC) at Week 52.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.